Analysts Offer Predictions for Sanara MedTech Q2 Earnings

Sanara MedTech Inc. (NASDAQ:SMTI) – Research analysts at HC Wainwright cut their Q2 2025 earnings estimates for Sanara MedTech in a note issued to investors on Thursday, May 15th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.33) per share for the quarter, down from their prior estimate of ($0.29). HC Wainwright currently has a “Buy” rating and a $53.00 price objective on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.10) per share. HC Wainwright also issued estimates for Sanara MedTech’s Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.28) EPS and FY2025 earnings at ($1.34) EPS.

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $46.00 target price on shares of Sanara MedTech in a research report on Wednesday, March 26th.

Sanara MedTech Trading Down 0.4%

Shares of SMTI opened at $31.04 on Monday. The stock’s fifty day simple moving average is $31.04 and its 200-day simple moving average is $33.42. The firm has a market capitalization of $275.88 million, a PE ratio of -31.35 and a beta of 1.38. Sanara MedTech has a 12-month low of $25.86 and a 12-month high of $39.08. The company has a quick ratio of 2.02, a current ratio of 2.23 and a debt-to-equity ratio of 0.76.

Sanara MedTech (NASDAQ:SMTI) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.10). The company had revenue of $23.43 million during the quarter, compared to the consensus estimate of $23.48 million. Sanara MedTech had a negative return on equity of 19.86% and a negative net margin of 10.71%.

Institutional Trading of Sanara MedTech

Institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC boosted its position in shares of Sanara MedTech by 8,423.8% in the 1st quarter. GAMMA Investing LLC now owns 1,790 shares of the company’s stock worth $58,000 after purchasing an additional 1,769 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in Sanara MedTech by 53.9% during the fourth quarter. Wells Fargo & Company MN now owns 1,893 shares of the company’s stock worth $63,000 after buying an additional 663 shares during the last quarter. MetLife Investment Management LLC acquired a new position in shares of Sanara MedTech during the 1st quarter worth about $82,000. BNP Paribas Financial Markets acquired a new position in shares of Sanara MedTech during the 4th quarter worth about $106,000. Finally, Rhumbline Advisers increased its stake in shares of Sanara MedTech by 14.9% in the 1st quarter. Rhumbline Advisers now owns 3,714 shares of the company’s stock valued at $115,000 after acquiring an additional 483 shares during the last quarter. Institutional investors and hedge funds own 8.10% of the company’s stock.

About Sanara MedTech

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.